Clinical Trials

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT02690558 2026-01-28

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

9 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

Phase 2 Recruiting

20 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03504163 2025-11-06

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

45 enrolled

Urinary Bladder Neoplasms

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1/2 Recruiting

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03978624 2025-10-15

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

20 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02365766 2025-03-18

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Phase 1/2 Completed

83 enrolled 14 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02662062 2025-01-27

PCR-MIB

28 enrolled 15 charts

Urinary Bladder Neoplasms

NCT03534804 2024-11-26

PemCab

37 enrolled 27 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02324582 2024-09-03

MARC

Phase 1 Completed

18 enrolled 11 charts

Urinary Bladder Neoplasms

NCT02808143 2024-06-26

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Phase 1 Completed

9 enrolled 13 charts

Urinary Bladder Neoplasms

NCT03319745 2024-06-25

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

23 enrolled 10 charts